Early Development Activities Clause Samples

Early Development Activities. 3.1.1 With respect to Collaboration Target 1, during the Research Term prior to Sanofi’s exercise of the Sanofi Participation Election Right with respect to Collaboration Target 1, Kymera will be solely responsible for (a) conducting all Pre-Clinical Development of Collaboration Candidates and Licensed Products Directed Against Collaboration Target 1 in the Field in the Territory, (b) filing all INDs therefor for the Indication(s) in the Field in the Territory, and (c) for conducting the Kymera Phase 1 Clinical Trials therefor, in each case ((a)-(c)) in accordance with the Early Development Plan (the “Early Development Activities”); provided that Kymera will not be required to commence the Kymera Phase 1 Clinical Trial with respect to the First Additional Degrader (i) while the Kymera Phase 1 Clinical Trial for any Initial Collaboration Target 1 Degrader is ongoing, (ii) if there is a Successful Completion of the Kymera Phase 1 Clinical Trials with respect to an Initial Collaboration Target 1 Degrader prior to commencement of the Phase 1 Clinical Trial with respect to the First Additional Degrader or (iii) following such Successful Completion, during the subsequent preparation or review of any Participation Data Package in accordance with Article 4. Kymera will be solely responsible for its costs and expenses of the Early Development Activities for First Additional Degraders. Sanofi will reimburse Kymera in accordance with Section 11.6.4 for [***] actually incurred by or on behalf of Kymera or its Affiliates for the Early Development Activities for Second Additional Degraders. 3.1.2 With respect to Collaboration Target 2, during the Research Term prior to Sanofi’s exercise of the Sanofi Participation Election Right with respect to Collaboration Target 2, Kymera will be solely responsible, at its cost and expense and in accordance with the applicable Early Development Plan, for (a) conducting all Pre-Clinical Development of Collaboration Candidates and Licensed Products Directed Against Collaboration Target 2 in the Field in the Territory, and (b) filing the first IND therefor for the first Indication in the Field in the first Major Market Country, in each case ((a)-(b)) in accordance with the Early Development Plan.